2D Intestinal Epithelial Cell Cultures for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vitro drug screening using intestinal epithelial cells face challenges due to the limited availability of primary human intestinal tissue and the limitations of using cancer cell lines and three-dimensional organoids, which do not accurately represent the physiology of intestinal epithelial cells, hindering the development of minimally systemic drugs.
Innovation Solution
The development of two-dimensional monolayer intestinal epithelial cell cultures from primary human and murine intestinal cells, using specific culture media compositions and conditions to generate cultures that are representative of endogenous intestinal epithelial cells, enabling high-throughput screening and drug evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If three-dimensional intestinal organoids are used for drug screening, then physiological relevance is improved, but device complexity and ease of operation deteriorate
Solution Approach 1:
The patent segments the complex three-dimensional organoid system into a simplified two-dimensional monolayer culture system that maintains key physiological features. By flattening the organoid structure into a monolayer, the system retains intestinal epithelial cell polarity and function while eliminating the operational complexity of maintaining 3D structures, enabling high-throughput screening capability.
Solution Approach 2:
The patent transitions from three-dimensional organoid cultures to two-dimensional monolayer cultures. This dimensional reduction simplifies the culture system architecture while preserving essential physiological characteristics such as cell polarity and barrier function, thereby improving ease of operation and high-throughput compatibility without completely sacrificing physiological relevance.
2Reliability
If primary human intestinal tissue is used, then physiological relevance is improved, but quantity of substance deteriorates
Solution Approach 1:
The patent employs preliminary actions by first establishing three-dimensional organoid cultures from limited primary human intestinal tissue, which then serve as a renewable source for generating two-dimensional monolayer cultures. This preliminary 3D cultivation step amplifies the limited starting material, providing sufficient cell numbers for high-throughput screening while maintaining human tissue physiological relevance.
Solution Approach 2:
The patent creates copies of primary human intestinal epithelial cells through organoid expansion and subsequent monolayer generation. The limited primary tissue serves as a template that can be replicated multiple times, producing sufficient quantities of physiologically relevant human intestinal cells for comprehensive drug screening without requiring additional primary tissue samples.
3Productivity
If cancer cell lines are used, then productivity is improved, but reliability deteriorates
Solution Approach 1:
The patent changes the key parameter of cell origin from cancerous to primary normal human intestinal epithelial cells. This parameter change maintains the productivity benefits of cultured cells while eliminating the physiological inaccuracies introduced by cancer cell line mutations and abnormal characteristics, thereby achieving both high throughput and physiological relevance.
Data Source
AI summary
Provided are compositions and methods for generating two-dimensional (2D) intestinal epithelial cell cultures for all segments of mouse and human small and large intestines. The compositions and methods described herein utilize primary human or murine intestinal cells and do not rely on cancer cell lines, resulting in 2D cultures that are representative of homeostatic epithelial gene expression and function. Also provided are compositions and methods of utilizing the cultures described herein in a high-throughput system for compound evaluation.